当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Alireza Mortazavi, Bevelacqua JJ, Rohit Gosain, Haghani M and SMJ Mortazavi
The apolipoprotein E gene is involved in Alzheimer's disease (AD). Individuals with at least one copy of APOE e4 gene are vulnerable to AD. Some studies show an association between Alzheimer's gene and higher risk of severe COVID-19. Oxidative stress plays a key role in COVID-19. Since respiratory viral infections are linked to pathophysiological processes such as cytokine production, inflammation, and cell death, they can be associated with a redox imbalance or oxidative stress. Moreover, Low Dose X-Ray Radiation (LDXR) may play a key role in prevention of Alzheimer's disease through mechanisms such as reducing the oxidative stress. In addition, recent studies indicate that low–moderate dose ionizing radiation (LMDIR) can directly ameliorate neurodegeneration and neuroinflammation. Thus, researchers have suggested that the therapeutic effects of LMDIR in AD might be mediated by its antiinflammatory and neuroprotective effects. By combining these approaches, we believe that low dose radiation therapy (LDRT) can open new horizons in treatment of the elderly patients with the Alzheimer's gene who suffer from severe pneumonia related to COVID-19. As most victims of the COVID-19 are elderly patients, this issue becomes more important. Clinical trials are underway related to using LDXR alone or in combination with one or more drugs/treatment methods in treating COVID-19. The results of these trials should determine the optimum LDRT parameters that can be beneficial for COVID-19 patients. It can be concluded that LDRT might offer a possible treatment protocol for COVID-19 patients with the Alzheimer's gene who need hospitalization and intensive care.